-
-
-
-
-
-
-
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
-
-
-
-
-
-
-
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
-
-
-
-
-
-
-
UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to $52 at Credit Suisse
-
-
-
-
-
-
-
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
-
-
-
-
-
-
-
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
-
-
-
-
-
-
-
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
-
-
-
-
-
-
-
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
-
13,127 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All